Results 51 to 60 of about 23,818,397 (163)
ABSTRACT Persistence of HCPs remains a major purification challenge in biopharmaceutical manufacturing with direct consequences for product quality, patient safety, and regulatory compliance. Over the last two decades, deeper insights into the mechanisms driving HCP persistence have clarified why certain proteins evade removal during purification ...
Younghoon Oh +10 more
wiley +1 more source
Engineered yeast microreactors that produce H2O2 within tumors enable selective cancer cell killing while releasing immunostimulatory components, effectively suppressing local tumor growth and activating systemic antitumor immunity, with further efficacy enhanced by anti‐PD‐1 therapy and transarterial embolization.
Wenqian He +9 more
wiley +1 more source
From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs
New approach methodologies (NAMs) encompass a diverse and rapidly evolving set of experimental and computational tools designed to generate human‐relevant mechanistic data for use in drug development and regulatory decision making. Experimental NAMs provide insights into drug disposition, pharmacological activity, and disease biology that are difficult
Karen Rowland Yeo, Piet H. van der Graaf
wiley +1 more source
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer +7 more
wiley +1 more source
Abstract BACKGROUND Recombinant protein expression in Escherichia coli frequently results in the formation of inclusion bodies (IBs), which provide high protein accumulation but often require additional steps to recover functional protein. Although culture conditions strongly influence IB physicochemical and structural characteristics, the impact of ...
Ximena Gómez‐Gil +7 more
wiley +1 more source
S.135-145The objective of the present study was to develop a physiologically based biopharmaceutics (PBBM) approach to predict the bioequivalence of dosage forms containing poorly soluble drugs.
Dressman, J.B., Kambayashi, A.
core +1 more source
Abstract Since the early 1960s, nanotechnology has been a critical area of science, allowing for the development of sophisticated nanomaterials. Nanofibers, one of the most widely used nanotechnological drug delivery systems, have emerged as a highly versatile platform within modern pharmaceutical sciences.
Heybet Kerem Polat +7 more
wiley +1 more source
At the solid–liquid interface, the dissolution of weakly basic drugs, particularly those exhibiting poor solubility, is highly sensitive to local pH conditions.
Venkata Krishna Kowthavarapu +6 more
doaj +1 more source
Ion Activation Methods for Top‐Down Proteomics
ABSTRACT Mass spectrometry (MS) has emerged as a premier method used to characterize the sequences of proteins. Top‐down proteomics aims to capture the multiple sources of structural diversity reflected in proteins, such as those that arise from alternative RNA splicing events or the addition of post‐translational modifications. Tandem MS (i.e., MS/MS)
Jada N. Walker, Jennifer S. Brodbelt
wiley +1 more source
This paper presents a case study demonstrating the application of model‐informed drug development (MIDD) and early modeling integration in the development of a sustained release (SR) formulation of flucytosine for cryptococcal meningoencephalitis (CM) in
Johanna Eriksson +8 more
doaj +1 more source

